Pancreatic Cancer Research

ResearcherUniversidad San Pablo CEUActive in the last 2 years

Benedetto Ielpo

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0003-3129-3208; OpenAlex author ID A5073254190. Sources: OpenAlex.

Their work

Papers
14 (first author 2, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
55
Papers, trials and grants by year

2013: 1 paper · 2014: 1 paper · 2015: none · 2016: 1 paper · 2017: 1 paper · 2018: 1 paper · 2019: 2 papers · 2020: 2 papers · 2021: none · 2022: none · 2023: 1 paper · 2024: 1 paper · 2025: 1 paper · 2026: 2 papers

Papers 14

  1. Benefit of adjuvant chemotherapy for resected pancreatic cancer following neoadjuvant FOLFIRINOX or Gemcitabine-Nab-paclitaxel: a multinational analysis. Co-author DOI 10.1093/jnci/djag235↗
  2. ASO Visual Abstract: Survival Benefit of Surgery Versus Oncology-Only Therapy in Artery-Involving Borderline Resectable and Locally Advanced Pancreatic Cancer. Co-author DOI 10.1245/s10434-025-18479-z↗
  3. Survival Benefit of Surgery versus Oncology-Only Therapy in Artery-Involving Borderline Resectable and Locally Advanced Pancreatic Cancer. Co-author DOI 10.1245/s10434-025-18212-w↗
  4. The impact of vascular margin invasion on local recurrence after pancreatoduodenectomy in pancreatic adenocarcinoma. First author DOI 10.1007/s00423-024-03301-3↗
  5. Minimally invasive versus open pancreatoduodenectomy for pancreatic ductal adenocarcinoma: Individual patient data meta-analysis of randomized trials. Co-author DOI 10.1016/j.ejso.2023.03.227↗
  6. Lymph Node Ratio, Perineural Invasion and R1 Resection as Independent Prognostic Factors in Pancreatic Adenocarcinoma: A Retrospective Cohort Study. First author PMID 32190897↗
  7. Prognostic Value of Lymph Node Status for Actual Long-Term Survival in Resected Pancreatic Cancer. Co-author PMID 32841360↗
  8. Venous Resection for Locally Advanced Pancreatic Cancer: Time Trend and Outcome Analysis of 65 Consecutive Resections at a High-Volume Center. Co-author DOI 10.1016/j.hpb.2022.05.919↗
  9. Impact of BRCA1/2 gene mutations on survival of patients with pancreatic cancer: A case-series analysis. Co-author DOI 10.14701/ahbps.2019.23.2.200↗
  10. The issue of how predict survival of patients affected by locally advanced pancreatic cancer. Co-author DOI 10.21037/atm.2018.12.41↗
  11. A comparative study of neoadjuvant treatment with gemcitabine plus nab-paclitaxel versus surgery first for pancreatic adenocarcinoma. Co-author DOI 10.1016/j.suronc.2017.08.003↗
  12. Preoperative treatment with gemcitabine plus nab-paclitaxel is a safe and effective chemotherapy for pancreatic adenocarcinoma. Co-author DOI 10.1016/j.ejso.2016.01.006↗
  13. Is arterial infiltration still a criterion for unresectability in pancreatic adenocarcinoma? Co-author DOI 10.1016/j.ciresp.2013.11.001↗
  14. Alternative arterial reconstruction after extended pancreatectomy. Case report and some considerations of locally advanced pancreatic cancer. Co-author DOI 10.6092/1590-8577/1468↗

Closest collaborators

The 25 strongest of 55 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Emilio Vicente · 8 shared papers, 2013–2026 · strength 0.78
  2. Elena B. Rangelova · 3 shared papers, 2025–2026 · strength 0.60
  3. Kongyuan Wei · 3 shared papers, 2023–2026 · strength 0.57
  4. Marc G. Besselink · 3 shared papers, 2023–2026 · strength 0.57
  5. Patricia Sánchez‐Velázquez · 2 shared papers, 2024–2026 · strength 0.47
  6. Riccardo R.C. Caruso · 7 shared papers, 2013–2020 · strength 0.46
  7. Yolanda Quijano · 7 shared papers, 2013–2020 · strength 0.46
  8. Fernando Burdı́o · 2 shared papers, 2023–2024 · strength 0.45
  9. Allegra Ripolli · 2 shared papers, 2025–2026 · strength 0.41
  10. Emanuele F. Kauffmann · 2 shared papers, 2025–2026 · strength 0.41
  11. Riccardo Casadei · 2 shared papers, 2025–2026 · strength 0.41
  12. Sergio Alfieri · 2 shared papers, 2025–2026 · strength 0.41
  13. V. Egorov · 2 shared papers, 2025–2026 · strength 0.41
  14. Gregory G. Tsiotos · 2 shared papers, 2025–2026 · strength 0.41
  15. Alessandro Zerbi · 2 shared papers, 2025–2026 · strength 0.41
  16. Yuichi Nagakawa · 2 shared papers, 2025–2026 · strength 0.41
  17. Niccolò Napoli · 2 shared papers, 2025–2026 · strength 0.41
  18. Ugo Boggi · 2 shared papers, 2025–2026 · strength 0.41
  19. Giuseppe Fusai · 2 shared papers, 2025–2026 · strength 0.41
  20. Roberto Coppola · 2 shared papers, 2025–2026 · strength 0.41
  21. Hipólito J. Durán · 6 shared papers, 2013–2020 · strength 0.37
  22. Carlos Plaza · 4 shared papers, 2016–2019 · strength 0.28
  23. Julio Cuesta López · 1 shared paper, 2024 · strength 0.28
  24. Syed A. Ahmad · 1 shared paper, 2026 · strength 0.19
  25. Giuseppe Malleo · 1 shared paper, 2026 · strength 0.19

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.